There are no related discussions.
Gilead and GlaxoSmithKline to commercialize Viread for chronic hepatitis B in key Asian countries; update on Avodart
Article | 26 November 2009
The USA’s Gilead Sciences and UK drug giant GlaxoSmithKline have signed a licensing agreement to commercialize the former’s Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies’ combined commercialization activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in most countries is more than 8%.
Under the deal, Gilead will retain exclusive rights for commercializing Viread for HBV in Hong Kong, Singapore, South Korea and Taiwan. In China, GSK will have exclusive rights and registration responsibilities for Viread for HBV. Each company will pay royalties to the other on sales of Viread for HBV in their respective Asian territories. Further financial terms were not disclosed. The companies are working to expand this agreement to include Japan and other countries.
Enjoying this article? Have the leading Biopharma news & analysis delivered daily on email by signing up for our FREE email newsletter here.
The Viread accord modifies the terms of the April 2002 licensing agreement between the two firms under which GSK received exclusive rights to Hepsera (adefovir dipivoxil), Gilead’s first hepatitis B treatment, in various territories including China, Japan, South Korea and Taiwan, as well as the right to commercialize Viread for the treatment of HBV under certain circumstances.GSK pulls Avodart sNDA
Meantime, GSK announced on November 23 that, in order to provide an update to the supplemental New Drug Application, it is temporarily withdrawing its sNDA for Avodart (dutasteride) for the reduction of prostate cancer risk among men at increased risk of developing the disease, because of what was described as an “administrative error” and not the result of new findings related to safety or efficacy of the drug.
The company plans to resubmit the filing shortly and confirmed that this action is not the result of new findings related to safety or efficacy. Review of European Union filings will begin once the same update is provided to EU regulatory agencies.
The latest discussion & debate from thepharmaletter.com discussion forums...
Gas Generators V Gas Cylinders
Peak Scientific Instruments have been established as a pioneer in Gas Generation since 1973 we are known worldwide for our excellent product range of on site gas generation
Promoting 'Safety and Efficiency in the Laboratory Environment.
Peak Scientific Instruments have a mission - to replace all cylinders. As a manufacturer of laboratory nitrogen, hydrogen & zero air gas generators they want to make everyone aware of the dangers & inconveniences of combustible gas cylinders. A Peak gas generator offers the safer solution to your gas needs by eliminating cylinders in the lab. Stop yourself worrying about the safe handling of gases, the safety valves, the explosion risk, the storage, the re-ordering & all the other things that go along with being a cylinder user - replace your cylinders with a safe, economical, endless supply of gas from a Peak generator.
Call Maureen on 0141 530 4168 or visit www.peakscientific.com
2010-01-28 09:33:10
Here just we are itroducing ourself.Barat Bioinformatics Research Institute (BBRI) is consultancy and service provider in the field of Bioinformatics and Information Technology. We aim at delivering innovative and customized Insilico solutions matched to the special needs of biotechnological and pharmaceutical origin. And we can deliever at intime datamining works.
contact
nagireddy@bbri.in visit us at www.bbri.in
2009-12-14 05:41:17
Hi all,
Apologies for the product placement here, but we just wanted to introduce ourselves. We host a lot of pharmaceutical conferences and would love to host more! If you are looking for a venue for a meeting, conference or event, Nottingham Conferences offers four flexible venues with excellent facilities, do get in touch if you are interested.
Give us a call on 0115 846 8000, visit www.nottinghamconferences.co.uk, or e-mail us at conferences@nottingham.ac.uk.
Thanks again for your time.
Kirstie
2009-12-11 11:05:02
